$7.0M
The investment round was led by an Asian corporate investor alongside existing backers to fund the commercial launch of Cyto-Mine.
"Sphere Fluidics Limited has recently successfully developed an alpha-version of its single cell analysis and characterization system (Cyto-Mine® for the biopharmaceutical discovery and development market. We have also convinced several leading biopharmaceutical companies to fund development of this system – indicating the global potential of the product. This new funding will used to develop the manufactured version of Cyto-Mine® (see image below) and enable its commercial launch later this year. This system is transformational for the Biopharmaceutical market."
